Better Buy: Ocugen vs. Pfizer
There are plenty of options when it comes to vaccine stock investing these days. You can choose a player that's already generating billions of dollars in sales from the vaccine and other products. Or you can bet on a latecomer that may see revenue and share gains down the road. So you might opt for vaccine leader Pfizer (NYSE: PFE), for example, or you might go for Ocugen (NASDAQ: OCGN) -- this company hasn't yet brought its vaccine candidate to market. Let's look at which may be the better buy right now.
Adria Cimino (Ocugen): Ocugen surged more than 700% in a matter of weeks earlier this year on optimism about potential coronavirus vaccine sales. The biotech company partnered with Bharat Biotech to co-commercialize that company's vaccine -- Covaxin -- in the U.S. The deal later expanded to include Canada. But Ocugen has struggled to actually bring Covaxin to market. As a result, shares have dropped 68% from their peak back in February.
Image source: Getty Images.
Source Fool.com
